High-dose ifosfamide plus adriamycin in the treatment of adult advanced soft tissue sarcomas: Is it feasible?

Annals of Oncology

Volumn 9, Issue 8, 1998, Pages 917-919

  De Pas, T ^a   De Braud, F ^a   Orlando, L ^a   Nole F ^a   Munzone, E ^a   Zampino, M G ^a   Fazio, N ^a   Aapro, M S ^a   Goldhirsch, A ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

Doxorubicin; High dose ifosfamide; Soft tissue sarcomas

Indexed keywords

DEXAMETHASONE; DOXORUBICIN; GRANISETRON; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; MESNA;

ADOLESCENT; ADULT; AGED; ANEMIA; ARTICLE; CLINICAL ARTICLE; CONTINUOUS INFUSION; DOSE RESPONSE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; NEUTROPENIA; PRIORITY JOURNAL; SOFT TISSUE SARCOMA; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTOPENIA;

EID: 0031690659     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008311901856     Document Type: Article

References (12)

1. Buonadonna A, Romanini A, Comandone A et al. Increasing continuous infusion ifosfamide and bolus epirubicin in soft tissue sarcoma patients. Proc Am Soc Clin Oncol 1996; 15 (Abstr 1683).
2. Reichardt P, Tilgner J. Mapara M et al. Dose intensive chemotherapy with or without stem cell support for adult patients with advanced soft tissue sarcoma: Final results of a phase II study and preliminar results of a phase I-II study. Proc Am Soc Clin Oncol 1997; 16 (Abstr 1791).
3. Patel SR, Vadhan-Raj S, Burgess MA et al. Dose intensive therapy does improve response rates update results of studies of adriamycin and ifosfamide with growth factors in patients with untreated soft tissue sarcomas. Proc Am Soc Clin Oncol 1997; 16 (Abstr 1794).
4. Bokemeyer C, Franzke A, Hartmann J et al. A phase I-II study of sequential, dose escalated, high-dose ifosfamide plus doxorubicin with peripheral blood stem cell support for the treatment of patients with advanced soft tissue sarcomas. Cancer 1997 (Oct 1); 80: 7.
5. Frustaci S, Buonadonna A, Galligioni E. Increasing 4′-epidoxorubicin and fixed ifosfamide doses plus granulocyte macrophage colony stimulating factor in advanced soft tissue sarcomas: A pilot study. J Clin Oncol 1997; 15 (4): 1418-26.
6. Bitran J, Samuels B, Marsik S et al. A phase 1 study of ifosfamide and doxorubicin with recombinant human granulocyte stimulating factor in stage IV breast cancer. Clin Cancer Res 1995; Feb: 185-8.
7. TM Loeffler, FW Weber, TH Hausamen. Ambulatory high-dose five-day continuous infusion ifosfamide combination chemotherapy in advanced solid tumours: A feasibility study. J Cancer Res Clin Oncol 1991; 117 (Suppl IV): S125-8.
8. Toma S, Palumbo R, Comandone A et al. Ambulatory four-day continuous infusion schedule of high-dose ifosfamide with mesna uroprotection and granulocyte colony stimulating factor in advanced solid tumours: A phase I study. Ann Oncol 1995; 6: 193-6.
9. Keizer HJ, Ouwerker J, Weelvaart K et al. Ifosfamide treatment as a 10-day continuous intravenous infusion. J Cancer Res Clin Oncol 1995; 121: 297-302.
10. Comandone A, Frustaci S, Bearz A et al. Efficacy and tolerability of an ifosfamide continuous infusion in soft tissue sarcoma patients. Abstract to CTOS, Milan, November 1997.
11. Skubitz KM. Early results of a phase II study of liposomal doxorubicin (Doxil) in refractory sarcoma. Proc Am Soc Clin Oncol 1997; 16 (Abstr 1830).
12. Garcia AA, Kempf R, Rogers M et al. Phase II study of Doxil (liposomal doxorubicin) in poor-prognosis adult soft tissue sarcoma. Proc Am Soc Clin Oncol 1997; 16 (Abstr 1818).